CorMedix Inc.

NasdaqGM CRMD

CorMedix Inc. Price to Sales Ratio (P/S) on January 14, 2025: 54.18

CorMedix Inc. Price to Sales Ratio (P/S) is 54.18 on January 14, 2025, a -91.72% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

CorMedix Inc. 52-week high Price to Sales Ratio (P/S) is 1,243.93 on April 11, 2024, which is 2,196.07% above the current Price to Sales Ratio (P/S).
CorMedix Inc. 52-week low Price to Sales Ratio (P/S) is 38.22 on September 30, 2024, which is -29.46% below the current Price to Sales Ratio (P/S).
CorMedix Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 473.83.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: CRMD

CorMedix Inc.

CEO	Mr. Joseph Todisco MBA
IPO Date	May 13, 2010
Location	United States
Headquarters	300 Connell Drive
Employees	82
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Key trends

Past 5 years